Biocon Biologics Paves the Way for Yesafili™ Launch in U.S. Market as an Interchangeable Biosimilar Biocon Biologics announces a significant settlement agreement, allowing Yesafili™, a biosimilar to Eylea®, to enter the U.S. market.

Biocon Biologics Paves the Way for Yesafili™ Launch in U.S. Market as an Interchangeable Biosimilar #United_States #Eylea #Bridgewater #Biocon_Biologics #Yesafili